{"filing":{"accession_number":"0001193125-26-249763","cik":"0001798749","ticker":"JBIO","company_name":"Jade Biosciences, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"d124589d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526249763/d124589d8k.htm"},"events":[{"id":7774,"run_id":6823,"accession_number":"0001193125-26-249763","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Jade Biosciences disclosed interim Phase 1 trial results for JADE101, a novel monoclonal antibody candidate for IgAN treatment, showing favorable safety, potent IgA reductions (approximately 70% at the 700 mg dose), and a differentiated pharmacokinetic profile. The results were presented via conference call and webcast and represent a material clinical development milestone affecting investor assessment of the company's pipeline progress and product viability.","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3104,"accession_number":"0001193125-26-249763","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Jade Biosciences is disclosing interim Phase 1 trial results for JADE101, a novel monoclonal antibody candidate for IgAN treatment, via a conference call and webcast. For a clinical-stage biopharmaceutical company, interim trial data disclosure is material to investors assessing pipeline progress and clinical viability, though it does not fit neatly into the standard taxonomy categories (not an earnings release, which typically refers to financial results). This is a material clinical development event disclosed under Regulation FD.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:21:16.107920+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3105,"accession_number":"0001193125-26-249763","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces interim Phase 1 clinical trial results for JADE101, a lead product candidate in development for IgAN treatment. The results show favorable safety, potent IgA reductions (approximately 70% at the 700 mg dose), and a differentiated pharmacokinetic profile supporting convenient dosing. While this is a clinical development milestone rather than a traditional earnings release, M\u0026A activity, or executive change, it represents material information about the company's pipeline progress that would affect a reasonable investor's assessment of the registrant's prospects and product development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:21:16.107920+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3104,"accession_number":"0001193125-26-249763","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Jade Biosciences is disclosing interim Phase 1 trial results for JADE101, a novel monoclonal antibody candidate for IgAN treatment, via a conference call and webcast. For a clinical-stage biopharmaceutical company, interim trial data disclosure is material to investors assessing pipeline progress and clinical viability, though it does not fit neatly into the standard taxonomy categories (not an earnings release, which typically refers to financial results). This is a material clinical development event disclosed under Regulation FD.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:21:16.107920+00:00","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-01"},{"id":3105,"accession_number":"0001193125-26-249763","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces interim Phase 1 clinical trial results for JADE101, a lead product candidate in development for IgAN treatment. The results show favorable safety, potent IgA reductions (approximately 70% at the 700 mg dose), and a differentiated pharmacokinetic profile supporting convenient dosing. While this is a clinical development milestone rather than a traditional earnings release, M\u0026A activity, or executive change, it represents material information about the company's pipeline progress that would affect a reasonable investor's assessment of the registrant's prospects and product development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:21:16.107920+00:00","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-01"}]}